Rechallenge with encorafenib and cetuximab after prior BRAF inhibitor therapy for colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving the drugs encorafenib and cetuximab again (rechallenge) can help people with BRAF V600E-mutant metastatic colorectal cancer whose disease has progressed after previous BRAF inhibitor-based therapy. It aims to see if this combination can be beneficial after a break from that type of treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to other parts of the body (metastatic).
- Your tumor has a specific mutation called BRAF V600E.
- You have already received at least 2 prior treatments for metastatic disease, including standard chemotherapy.
- You previously received a BRAF inhibitor combination (like encorafenib) for at least 4 months, and your cancer was controlled for more than 6 months.
- Your cancer has progressed during or within 6 months of your last treatment regimen.
- You are able to take pills by mouth and have adequate organ function (blood, liver, kidney, heart).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapies for people with metastatic colorectal cancer that has a specific BRAF V600E mutation and has progressed after initial treatment. The goal is to see if this combination can shrink tumors or stop them from growing further.
This trial tests a combination of three drugs (cetuximab, irinotecan, and envafolimab) as a ‘rechallenge’ – meaning if you had good results with cetuximab or irinotecan before, trying them again with a new drug might help shrink or control your cancer.
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
This study tests a new approach for people with a specific type of metastatic colorectal cancer that has stopped responding to initial treatments. It compares reusing a targeted drug combination (irinotecan plus cetuximab) versus a different chemotherapy plus a targeted drug (trifluridine/tipiracil plus bevacizumab) to see which works better for patients whose tumors have a certain genetic profile.
This trial tests whether giving encorafenib and cetuximab before surgery can shrink or control BRAF-mutated colon or upper rectal cancer and make surgery more effective. It also checks whether this approach is safe and helps patients do better overall.
This trial tests if combining three targeted drugs (cetuximab, encorafenib, and binimetinib) before surgery can shrink or control cancer in people with a specific BRAF V600E mutation and a stable (MSS) tumor. It focuses on colorectal cancer that is either already able to be removed or could become removable with treatment.
Hear when a new Colo-rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.